Histogenics to Explore Strategic Alternatives for NeoCart Cartilage Treatment
Histogenics plans to evaluate the range of potential strategic alternatives for its NeoCart® cell therapy following FDA's indication that an additional clinical trial would be required before acceptance of a Biologics License Application submission. Jan 03, 2019